Diana Evans, MS CCC-SLP in Belle Mead, NJ - Speech-Language Pathologist

Diana Evans, MS CCC-SLP is a Speech-language Pathologist based in Belle Mead, New Jersey. Diana Evans is licensed to practice in New Jersey (license number 41YS00647200) and her current practice location is 111 Cain Ct, Belle Mead, New Jersey. She can be reached at her office (for appointments etc.) via phone at (609) 915-7637.

NPI number for Diana Evans is 1295181378 and her current mailing address is 111 Cain Ct, Belle Mead, New Jersey. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1295181378.

Contact Information

	Diana Evans, MS CCC-SLP
	111 Cain Ct, Belle Mead, NJ 08502-6405
	(609) 915-7637
	Not Available

Healthcare Provider's Profile

Full Name	Diana Evans
Gender	Female
Speciality	Speech-language Pathologist
Location	111 Cain Ct, Belle Mead, New Jersey
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1295181378
Provider Enumeration Date: 05/09/2016
Last Update Date: 05/09/2016

Medical Identifiers

Medical identifiers for Diana Evans such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1295181378	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
235Z00000X	Speech-language Pathologist	41YS00647200 (New Jersey)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Diana Evans is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Diana Evans, MS CCC-SLP 111 Cain Ct, Belle Mead, NJ 08502-6405 Ph: (609) 915-7637	Diana Evans, MS CCC-SLP 111 Cain Ct, Belle Mead, NJ 08502-6405 Ph: (609) 915-7637

News Archive

Two related enzymes play a key role in development of T-ALL

Columbia University Medical Center (CUMC) scientists have demonstrated that two related enzymes - phosphoinositide-3 kinase (PI3K) gamma and delta - play a key role in the development of T-cell acute lymphoblastic leukemia (T-ALL), a highly aggressive childhood leukemia that is difficult to treat.

Solomon Islands' media should increase HIV/AIDS awareness, combat stigma, official says

Media outlets in the Solomon Islands should undertake efforts to increase awareness about HIV/AIDS and counteract the stigma associated with the disease, Joe Weber, Oxfam International representative for the country, said recently at the close of a week-long media training on HIV/AIDS and sexually transmitted infections, PINS/Solomon Star News reports.

Oncolytics signs equity distribution agreement with Canaccord Genuity

Oncolytics Biotech Inc. announced today that it has entered into an "at-the-market" (ATM) equity distribution agreement with Canaccord Genuity Inc. acting as sole agent.

BrainStorm completes registered public offering of common stock

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced that it completed a registered public offering of 19,818,972 shares of common stock at a price per share of $0.29 and warrants to purchase 14,864,229 shares of common stock at an exercise price of $0.29 per share, representing gross proceeds of $5,747,502.

Oramed Pharmaceuticals submits study protocol to FDA for Phase IIb trial of ORMD-0801

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted the study protocol for the company's Phase IIb trial of ORMD-0801, its oral insulin capsule, to the U.S. Food and Drug Administration.

Diana Evans, MS CCC-SLP - Speech-Language Pathologist in Belle Mead, NJ